Medication info

Rocarb Tablets 30/10 mg

Prescription medicationTabletOral
Ingredient · strength
Fimasartan Potassium Trihydrate Granules›75mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Green, convex, octagonal film-coated tablets
Packaging
30 tablets (10 tablets/PTP packaging x 3), 100 tablets (10 tablets/PTP packaging x 10)
Approval status
Active

MFDS item code 201700489 · Approved 2017.01.25

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. (See section 9, Administration to Older Adults, under Precautions for Use.) 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment (see section 2, Patients in Whom the Medicine Must Not Be Administered, and section 10, Administration to Patients with Hepatic Impairment, under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3, Administration with Caution, under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
View approved original text

This medicine is suitable for patients who use both active ingredients, pimasartan and rosuvastatin. Pimasartan is used to treat essential hypertension. Rosuvastatin is used as an adjunct when hyperlipidemic conditions such as primary hypercholesterolemia and mixed hyperlipidemia, as well as dysbetalipoproteinemia, are not sufficiently controlled by diet. Additionally, rosuvastatin helps lower cholesterol levels in patients with hypercholesterolemia, slowing the progression of atherosclerosis and reducing the risk of cardiovascular diseases. It has a positive effect on reducing the need for stroke, myocardial infarction, and vascular revascularization procedures in the elderly and those with various risk factors. Therefore, this medicine is used to manage hypertension and hyperlipidemia simultaneously to reduce the risk of cardiovascular diseases.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. (See section 9, Administration to Older Adults, under Precautions for Use.) 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment (see section 2, Patients in Whom the Medicine Must Not Be Administered, and section 10, Administration to Patients with Hepatic Impairment, under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3, Administration with Caution, under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Precautions

This medicine can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to any of the ingredients of this medicine, those with severely impaired liver function, very poor kidney function, or certain muscle diseases should not take this medicine. Patients with low blood volume or low salt levels in the body may experience a rapid drop in blood pressure soon after starting this medication, so they should be monitored closely. Patients with weak kidney function or renal artery hypertension, as well as patients with heart valve diseases, should discuss this medication thoroughly with their healthcare provider before taking it. This medicine can cause muscle pain, weakness, and rarely serious muscle damage, so any unusual symptoms in the muscles during treatment should be reported to a healthcare provider immediately. Liver function abnormalities or hepatitis symptoms may occur, so it is advisable to undergo regular liver function tests before and during treatment. This medicine may interact with other medications, so if you are taking any other drugs, you must inform your healthcare provider. Women who may become pregnant should use appropriate contraception, and it is safest not to take this medicine during pregnancy or while breastfeeding. Elderly patients or those with impaired liver function should exercise additional caution while taking this medicine, and dose adjustments may be necessary. Dizziness may occur while driving or operating machinery during treatment, so caution is advised. Keep this medicine out of the reach of children and do not transfer it to another container.

Side effects

Indigestion, nausea, fever, hepatitis, headache, dizziness, upper abdominal pain, esophagitis, gastroenteritis, nasopharyngitis, tonsillitis, upper respiratory tract infection, elevated ALT, elevated γ-GTP, increased liver enzyme levels, increased white blood cell count, urinary disorders, increased urination, cough, hyperkalemia, joint pain, insomnia, itching, syncope, sedation, migraine, vomiting, weakness, foreign body sensation, decreased platelet count, increased serum creatine phosphokinase, muscle contraction, myalgia, flushing, erythema, erectile dysfunction, angioedema, diabetes, constipation, abdominal pain, pancreatitis, rash, urticaria, muscle aches, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, contusion, epilepsy, amyotrophic lateral sclerosis, neuropathy, neuronitis, facial paralysis, normal pressure hydrocephalus, spinal stenosis, acute pancreatitis, bowel obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, exacerbation of cerebral infarction, cerebral hemorrhage, liver cancer, colorectal carcinoma, neoplasm of unknown origin, cervical cancer, prostate cancer, acute renal failure, chronic renal failure, renal stone, pyelonephritis, urinary incontinence, rhinitis, fibrotic alveolitis, pharyngitis, pneumonia, lung disease, death, exacerbation of low back pain, osteoarthritis, arthrosis, hypoglycemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, coronary artery disease, aortic stenosis, heart failure, hypertension, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, chest pain, low back pain, limb pain, facial edema, fatigue, fever, neck/shoulder pain, fracture, osteoporosis, pharyngitis, upper respiratory tract infection, sputum, rhinitis, nosebleed, bronchitis, paresthesia, numbness, tremor, excessive muscle tone, anxiety, memory impairment, loss of appetite, gastroesophageal reflux, gastritis, diarrhea, functional bowel disorder, gastroenteritis, increased urination, urinary incontinence, renal stone, chronic renal failure, dysuria, hyperlipidemia, dyslipidemia, hypoglycemia, hypertension, purpura, fatty liver, localized inflammation, soft tissue infection, lymphadenopathy, laceration of unspecified nature, septal deviation, surgical intervention, postoperative pain, heat intolerance, fall, allergy, chills, nasal polyps, edema, peripheral edema, fatigue, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, generalized pain, muscle cramps, gout, erectile dysfunction, contusion

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medicine in a tightly closed container to prevent exposure to air and moisture, and keep it at room temperature between 1°C and 30°C. Storing in this manner will maintain the effectiveness of the medicine and ensure safe usage.

Appearance and packaging

Appearance

Green, convex, octagonal film-coated tablets

Package unit

30 tablets (10 tablets/PTP packaging x 3), 100 tablets (10 tablets/PTP packaging x 10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.